Subscribe to Search results

Dr Anna Pettigrew took up post as a part-time clinical assistant at the Royal Hospital for Sick Children.

Published on:

Dr Pettigrew recollected that newly diagnosed patients or those with mild haemophilia were treated with cryoprecipitate and those on home therapy or frequent attending patients were treated with concentrate.

Published on:

Dr Pettigrew recalled commercial product was more user friendly and dissolved quicker.

Published on:

Parents often administered home therapy which was preferred.

Published on:

Home therapy and prophylactic therapy were introduced by Dr Willoughby for psychological and clinical reasons.

Published on:

Dr Pettigrew viewed that all clinical staff acted in what they thought to be in the best interests of their patients, including Dr Willoughby (who instituted home therapy with Factor VIII concentrates.

Published on:

Cryoprecipitate, although less convenient to use, was not impracticable for home treatment despite what the opinion at Yorkhill hospital was.

Published on:

Glasgow Yorkhill Haemophilia Centre's annual returns showed substantial but decreasing use of commercial compared to PFC concentrates.

Published on:

RHSC annual return showed 62,315 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 123,998 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 354,276 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 682,732 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 629,697 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 485,880 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 36,850 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 5,460 units of commercial concentrate was used for haemophilia treatment.

Published on:

Dr Willoughby did not realise that commercial Factor VIII concentrates were exposing patients to the risk of viral infections until around 1983.

Published on:

Professor Ian Hann stated that 21 children at the RHSC were infected with HIV relatively early in the HIV crisis, "probably as a result of the widespread use of commercial product."

Published on:

Dr Geoffrey Tovey published a statement regarding the introduction of heat-treated concentrates into the Bristol Haemophilia Centre. His policy was to use NHS products in preference to commercial products and where there was a shortfall of NHS products, priority was given to children and adults known to be hepatitis and HIV negative.

Published on:

Dr Geoffrey Scott complained to Dr Geoffrey Tovey about the insolubility of the Elstree Factor 8 concentrate which meant it could no longer be used for home treatment and therefore more commercial Factor VIII would need to be purchased.

Published on: